MAPT and Alzheimer disease: The activation of MAPK-ERK1/2 is associated with neurofibrillary tangles in AD [52], and modulation of P38α MAPK may potentially reduce beta-amyloid production, tau hyperphosphorylation, synaptic dysfunction and behavioural deficits [53–55].